about
Genetic methods in diagnosis of hematooncological disordersChromosome 1 amplification has similar prognostic value to del(17p13) and t(4;14)(p16;q32) in multiple myeloma patients: analysis of real-life data from the Polish Myeloma Study Group.Changes in T-cell subpopulations and cytokine network during early period of ibrutinib therapy in chronic lymphocytic leukemia patients: the significant decrease in T regulatory cells number.Th17/IL-17A might play a protective role in chronic lymphocytic leukemia immunity.The rate of in vitro fludarabine-induced peripheral blood and bone marrow cell apoptosis may predict the chemotherapy outcome in patients with chronic lymphocytic leukemiaDanazol induces apoptosis and cytotoxicity of leukemic cells alone and in combination with purine nucleoside analogs in chronic lymphocytic leukemia.Assessment of red blood cell distribution width as a prognostic marker in chronic lymphocytic leukemia.Resveratrol increases rate of apoptosis caused by purine analogues in malignant lymphocytes of chronic lymphocytic leukemiaAdditional genetic abnormalities significantly worsen poor prognosis associated with 1q21 amplification in multiple myeloma patients.CD1d expression is higher in chronic lymphocytic leukemia patients with unfavorable prognosis.BAFF and APRIL expression in B-cell chronic lymphocytic leukemia: correlation with biological and clinical features.The yield of endobronchial biopsy in pulmonary sarcoidosis: connection between spirometric impairment and lymphocyte subpopulations in bronchoalveolar lavage fluid.Intracellular IL-4 and IFN-γ expression in iNKT cells from patients with chronic lymphocytic leukemia.TP53 polymorphism in plasma cell myeloma.Molecular cytogenetic analysis of a familial interstitial deletion Xp22.2-22.3 with a highly variable phenotype in female carriers.The candidate immunotherapeutical target, the receptor for hyaluronic acid-mediated motility, is associated with proliferation and shows prognostic value in B-cell chronic lymphocytic leukemia.Cytotoxic activity of valproic acid on primary chronic lymphocytic leukemia cells.The function of a novel immunophenotype candidate molecule PD-1 in chronic lymphocytic leukemia.Assessment of micro RNAs expression in leukemic cells as prognostic markers in chronic lymphocytic leukemia: micro RNAs can predict survival in a course of the disease.Polymorphisms in the promoter region of the CRBN gene as a predictive factor for the first-line CTD therapy in multiple myeloma patients.The clinical significance of interleukin 18 assessment in sarcoidosis patientsTumor necrosis factor receptors (TNFRs) on T lymphocytes and soluble TNFRs in different clinical courses of sarcoidosis1q21 amplification with additional genetic abnormalities but not isolated 1q21 gain is a negative prognostic factor in newly diagnosed patients with multiple myeloma treated with thalidomide-based regimensExpression of Programmed Death 1 Ligand in Different Compartments of Chronic Lymphocytic LeukemiaThalidomide can promote erythropoiesis by induction of STAT5 and repression of external pathway of apoptosis resulting in increased expression of GATA-1 transcription factor
P50
Q26853326-C4E1227D-2E14-4213-86F3-4D180C76C061Q31154933-44B734A7-6EBF-4308-BD0C-36DD50C1D3A1Q33798525-ADE9DC51-FF4E-46E4-8A4C-63387A84E282Q35040785-6FEA3373-E501-4B0C-A4B1-DC14A9498DFFQ35941236-15D7279B-5AAE-43AA-B94B-0782C2D19785Q36547670-A200FE17-4D33-49D9-8DBB-F2B32AFAC7C3Q37362785-9DB96116-AE6A-415C-B6B3-8BD7FD6782AEQ42159065-573838D4-81E1-4FB1-ACAF-9F8628896F77Q44554207-0D3B1CA0-693B-420D-ACA3-E5164EFBA7F2Q46728347-302AA97C-3E4E-459B-88DF-1B4393AD4A57Q47939939-D4932BF8-2B80-48FD-94C0-2B9F7FBDD783Q48020575-ACBA3897-93AB-42A2-9757-84C736EAA738Q49428366-07CD9410-CC3A-411D-A5D6-8DA6229DE122Q50048709-BD319D6C-37C2-45AB-B1C5-5D408F8FA223Q51921455-94E6565E-9B0D-4FE7-ACC5-CF7BF3837B1CQ53429971-ED234121-504D-44B1-9649-8BB83F251CE3Q53525341-2C0C31B3-82F6-4822-BF6F-A52795328AA0Q54290307-C5F6FA34-8AC3-4B13-9B42-C8BBB52A1D33Q55182677-1806A8D2-067F-4955-9A85-27263B2CD62EQ55309345-BB9174B0-3D0A-43AA-A031-C8BBDDDEF424Q79172823-221E70BA-1EA3-4D25-8735-2C3C7F693D80Q80062399-9233E0A4-CF46-4540-ABA0-A5F231EE089CQ83873603-63D4EECA-19BD-4B5C-9182-CA82C3C0576DQ85565030-32835737-97F2-4C28-AC3B-9BC143BFD900Q86514143-B704AA5A-B093-42C2-B7AA-E138C393128A
P50
description
researcher ORCID ID = 0000-0002-5001-9258
@en
wetenschapper
@nl
name
Sylwia Chocholska
@ast
Sylwia Chocholska
@en
Sylwia Chocholska
@es
Sylwia Chocholska
@nl
Sylwia Chocholska
@pl
type
label
Sylwia Chocholska
@ast
Sylwia Chocholska
@en
Sylwia Chocholska
@es
Sylwia Chocholska
@nl
Sylwia Chocholska
@pl
prefLabel
Sylwia Chocholska
@ast
Sylwia Chocholska
@en
Sylwia Chocholska
@es
Sylwia Chocholska
@nl
Sylwia Chocholska
@pl
P214
P106
P1153
6507412205
P214
P31
P3124
P496
0000-0002-5001-9258
P7859
viaf-311797581